Lower Dose Nucala Safe, Effective in EGPA With Fewer Adverse Events

Lower Dose Nucala Safe, Effective in EGPA With Fewer Adverse Events

305247

Lower Dose Nucala Safe, Effective in EGPA With Fewer Adverse Events

A lower, 100 mg dose of Nucala (mepolizumab) is equally effective at treating eosinophilic granulomatosis with polyangiitis (EGPA) as the standard 300 mg dose, and leads to less frequent adverse events, or AEs, a large European study showed. These findings suggest that a lower monthly dose of Nucala could be acceptable for people with this form of ANCA-associated vasculitis, though randomized clinical trials should be conducted to confirm the benefits, the researchers said. “At all…

You must be logged in to read/download the full post.